ScRNA-seq also demonstrated that CRC cells treated with FTD have a lower expression of HLA-I molecules, B2M, and TAP1 (Fig. 3E), all involved in antigen presentation and commonly downregulated in cancers as a mechanism of immune escape33,44–46. Here, B2M is linked to cancer.